GlassScriptPhysician profile
Justin Dawson
NPI 1740279553
$6,776.75
in general payments reported to CMS, 2019-2025
35 companies · $880 in 2025
The $880 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,130 · 2020: $688 · 2021: $1,052 · 2022: $884 · 2023: $1,176 · 2024: $967 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,922.72 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,297.12 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,151.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $993.94 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $560.37 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novartis Pharmaceuticals Corporation | $437.32 | 2019-2023 | |
| Astellas Pharma US INC | $378.16 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $313.20 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $192.57 | 2019-2021 | |
| Pfizer INC. | $186.44 | 2019-2025 | |
| Glaxosmithkline, LLC. | $154.14 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $134.88 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $109.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $103.25 | 2019-2023 | M-M-R II, Gardasil 9, Vaxelis |
| Otsuka America Pharmaceutical, INC. | $96.80 | 2024-2025 | Rexulti |
| Allergan, INC. | $69.99 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $68.41 | 2021 | |
| Lundbeck LLC | $62.05 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $55.93 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $46.86 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.29 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.46 | 2022 | |
| Sunovion Pharmaceuticals INC. | $35.01 | 2021-2022 | |
| Exact Sciences Corporation | $30.28 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.27 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $27.04 | 2020 | |
| Supernus Pharmaceuticals, INC. | $22.91 | 2021 | |
| Corcept Therapeutics | $22.54 | 2023 | Korlym |
| Averitas Pharma INC. | $22.39 | 2024 | Qutenza |
| Sanofi Pasteur INC. | $20.99 | 2022 | |
| Amarin Pharma, INC. | $20.61 | 2020 | |
| Boston Scientific Corporation | $17.53 | 2024 | Watchman Access System |
| Daiichi Sankyo INC. | $13.93 | 2024 | Injectafer |
| Dexcom, INC. | $13.01 | 2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $11.19 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.